跳至主要内容
临床试验/IRCT20200419047128N1
IRCT20200419047128N1已完成2 期

Assessment of the effect of Tranilast (novel NLRP3 Inflammasome inhibitor ) on the efficacy of antiviral drug regimens in the treatment of patients with severe COVID19

Ahvaz University of Medical Sciences0 个研究点目标入组 60 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
已完成
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 85 years(—)
性别
All

入选标准

  • Age =18 years
  • Laboratory polymerase chain reaction (PCR) confirmed infection with COVID19
  • Lung involvement confirmed with chest imaging Hospitalized with: Fever Or Cough Less than 8 days since illness onset
  • Willingness of study participant to accept randomization to any assigned treatment arm
  • Acceptance of non-participation in another study before the 28th day of the study
  • arterial blood O2 saturation under 93%
  • non-pregnant females

排除标准

  • Autoimmune diseases (lupus, MS, etc.)
  • Hepatic failure
  • Hepatit B, C,
  • pregnant and lactating women
  • use of antioxidants, anti-inflammatory and immunosuppressant drugs
  • kidney failure
  • known allergy to Tranilast

研究者

相似试验